A Dye for the Detection of Cancer of the Tongue and Mouth



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:March 15, 2017
End Date:July 2019
Contact:Heiko Schoder, MD
Email:schoderh@mskcc.org
Phone:212-639-2079

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas

The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used
to detect this type of cancer. This will be the first time that PARPi-FL is being tried in
people. First, the investigators will test the safety of PARPi-FL at different doses to find
out what effects, if any, it has on people. The investigators will also see which amount of
PARPi-FL is best suited to detect cancers of the mouth and tongue.


Inclusion Criteria:

- Patient is ≥ 18 years old

- Histologically or cytologically proven squamous cell carcinoma of the oral cavity or
pharynx (OSCC)

- Scheduled to undergo surgery at MSK

- Any tumor stage, any N, M0

- ECOG performance status 0 or 1

Exclusion Criteria:

- Any surgical therapy in the area of the oral cavity or pharynx within the last 2 weeks

- Prior or ongoing treatment with a PARP1 inhibitor

- Known hypersensitivity to Olaparib

- Known hypersensitivity to PEG300 Eligibility criteria will be assessed by an
experienced oral surgeon, typically the Co-PI of the study.
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Heiko Schoder, MD
Phone: 212-639-2079
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials